SpyGlass Pharma and Agomab Therapeutics filed for initial public offerings following investor interest sparked at J.P. Morgan Healthcare Conference. Both drug developers aim to leverage the window of investor enthusiasm after recent biotech listings and to fund late‑stage development and commercial planning. The filings underscore sustained IPO appetite for clinical‑stage immuno‑ and GI‑focused companies, but successful listings will hinge on readouts, regulatory clarity and market receptivity in coming quarters.